Important update: Healthcare facilities
CDC has updated select ways to operate healthcare systems effectively in response to COVID-19 vaccination. Learn more
Given new evidence on the B.1.617.2 (Delta) variant, CDC has updated the guidance for fully vaccinated people. CDC recommends universal indoor masking for all teachers, staff, students, and visitors to K-12 schools, regardless of vaccination status. Children should return to full-time in-person learning in the fall with layered prevention strategies in place.
The White House announced that vaccines will be required for international travelers coming into the United States, with an effective date of November 8, 2021. For purposes of entry into the United States, vaccines accepted will include FDA approved or authorized and WHO Emergency Use Listing vaccines. More information is available here.
Travel requirements to enter the United States are changing, starting November 8, 2021. More information is available here.

Clinical Care Information for COVID-19

Clinical Care Information for COVID-19
Updated Jan. 30, 2023
Doctor providing patient care
Caring for Patients

Clinical considerations for children and adults with COVID-19, including clinical diagnosis, management, and more.

Clinical Care Considerations
Doctor providing patient care

Looking for information on treatments? Outpatient Treatment Overview

Managing COVID-19 Patients

Quick Reference

Highlights key COVID-19 clinical information for healthcare providers and provides selected links to full guidance.

Pre-Exposure Prophylaxis

EVUSHELDTM, a monoclonal antibody combination that was used for pre-exposure prophylaxis to protect against SARS-CoV-2 infection, is not currently authorized for emergency use in the United States because it is unlikely to be active against certain SARS-CoV-2 variants. According to the most recent CDC Nowcast data, these variants are projected to be responsible for more than 90% of current infections in the U.S. This means that Evusheld is not expected to provide protection against developing COVID-19 if exposed to those variants. Healthcare facilities and providers with EVUSHELDTM should retain all products in the event that SARS-CoV-2 variants that are neutralized by EVUSHELDTM become more prevalent in the U.S. in the future. For more information, see FDA’s announcement.

Guidance by Patient Type

Multisystem Inflammatory Syndrome in Children

Healthcare providers who have cared or are caring for patients younger than 21 years of age meeting criteria for multisystem inflammatory syndrome in children (MIS-C) should report suspected cases to their local, state, or territorial health department.

For additional reporting questions, please contact CDC’s 24-hour Emergency Operations Center at 770-488-7100.

Names of specific vendors, manufacturers, or products in this collection of content are included for public health and informational purposes; inclusion does not imply endorsement of the vendors, manufacturers, or products by the Centers for Disease Control and Prevention or the US Department of Health and Human Services.